Proton Arc Therapy has the potential to improve dose conformity to the tumor while further reducing dose to the adjacent surrounding healthy tissue and ultimately increasing treatment effectiveness. 

IBA invites you to attend a webinar co-organized with ESTRO and presented by Yves Jongen, IBA's founder and the two leading figures in Proton Arc Therapy, Dr. Kabolizadeh and Dr. Ding from the Beaumont Health Proton Therapy Center.

The IBA Proton Arc Therapy Strategy will also be presented by Francois Sergent, IBA clinical Solution Manager and Cedric Osterrieth, IBA Product Manager.

Arc Therapy is currently under research and development phase and will be available for sale when regulatory clearance is received.